Patent · US Active

Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

US11851434B2 · kind B2 · utility

0Cited by

82References

16Claims

0Family size

Assignee

Array BioPharma, Inc. · US

Inventors

Steven W. Andrews · Longmont, US
James F. Blake · Longmont, US
Julia Haas · Boulder, US
Yutong Jiang · Boulder, US
Gabrielle R. Kolakowski · Boulder, US
David A. Moreno · Boulder, US
Li Ren · Superior, US
Shane M. Walls · Lafayette, US

Key dates

Filing date	Oct 29, 2021
Grant date	Dec 26, 2023
Priority date	—
Expiry date	Feb 25, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.